Health In Tech, Inc. Class A Common Stock (HIT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Health In Tech, Inc. Class A Common Stock stock (HIT) is currently trading at $1.81. Health In Tech, Inc. Class A Common Stock PE ratio is 90.00. Health In Tech, Inc. Class A Common Stock PS ratio (Price-to-Sales) is 3.33. Analyst consensus price target for HIT is $4.50. WallStSmart rates HIT as Sell.
- HIT PE ratio analysis and historical PE chart
- HIT PS ratio (Price-to-Sales) history and trend
- HIT intrinsic value — DCF, Graham Number, EPV models
- HIT stock price prediction 2025 2026 2027 2028 2029 2030
- HIT fair value vs current price
- HIT insider transactions and insider buying
- Is HIT undervalued or overvalued?
- Health In Tech, Inc. Class A Common Stock financial analysis — revenue, earnings, cash flow
- HIT Piotroski F-Score and Altman Z-Score
- HIT analyst price target and Smart Rating
Health In Tech, Inc.
📊 No data available
Try selecting a different time range
HIT Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Health In Tech, Inc. Class A Common Stock (HIT)
HIT trades 130% above its Graham fair value of $0.47, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Health In Tech, Inc. Class A Common Stock (HIT) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Health In Tech, Inc. Class A Common Stock (HIT) Key Strengths (1)
Revenue surging 90.40% year-over-year
Supporting Valuation Data
Health In Tech, Inc. Class A Common Stock (HIT) Areas to Watch (8)
Very thin margins with limited operational efficiency
Very expensive at 6.0x book value
Very thin margins, barely profitable
Very low institutional interest at 4.79%
Micro-cap company with very limited liquidity and high volatility
Moderate profitability with room for improvement
Revenue is fairly priced at 3.33x sales
Solid earnings growth at 10.30%
Supporting Valuation Data
Health In Tech, Inc. Class A Common Stock (HIT) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 3.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 90.40%.
The Bear Case
The primary concerns are Operating Margin, Price/Book, Profit Margin. Some valuation metrics including Price/Sales (3.33), Price/Book (6.00) suggest expensive pricing. Growth concerns include EPS Growth at 10.30%, which may limit upside. Profitability pressure is visible in Return on Equity at 11.90%, Operating Margin at 5.81%, Profit Margin at 4.68%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 11.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 90.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HIT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HIT's Price-to-Sales ratio of 3.33x sits near its historical average of 3.18x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 5% below its historical high of 3.52x set in Mar 2026, and 28% above its historical low of 2.61x in Feb 2026. Over the past 12 months, the PS ratio has expanded from ~2.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Health In Tech, Inc. Class A Common Stock (HIT) · TECHNOLOGY › SOFTWARE - APPLICATION
The Big Picture
Health In Tech, Inc. Class A Common Stock is a strong growth company balancing expansion with improving profitability. Revenue reached 31M with 90% growth year-over-year. Profit margins are strong at 468.0%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 90% YoY, reaching 31M. This pace significantly outperforms most SOFTWARE - APPLICATION peers.
ROE of 1190.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -939,399, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Health In Tech, Inc. Class A Common Stock maintain 90%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 90.0x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor SOFTWARE - APPLICATION industry trends, competitive moves, and regulatory changes that could impact Health In Tech, Inc. Class A Common Stock.
Bottom Line
Health In Tech, Inc. Class A Common Stock offers an attractive blend of growth (90% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Health In Tech, Inc. Class A Common Stock(HIT)
NASDAQ
TECHNOLOGY
SOFTWARE - APPLICATION
USA
Health In Tech, Inc. (HIT) is a pioneering force in the convergence of healthcare and technology, committed to revolutionizing care delivery through cutting-edge digital solutions. Leveraging advanced data analytics and proprietary software, HIT enhances decision-making capabilities for healthcare providers and patients alike, thereby elevating patient outcomes and operational efficiencies. With a strong emphasis on compliance and cybersecurity, the company is strategically positioned to capitalize on the burgeoning growth of the digital health market. As the demand for innovative, technology-driven healthcare solutions accelerates, HIT is well-equipped to emerge as a leading player in this transformative landscape.